Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2019

Open Access 01-12-2019 | Underweight | Research article

Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis

Authors: Huiquan Liu, Lu Li, Jun Zou, Ting Zhou, Bangyan Wang, Huihui Sun, Shiying Yu

Published in: BMC Complementary Medicine and Therapies | Issue 1/2019

Login to get access

Abstract

Background

Cancer cachexia is a cancer-induced multifactorial debilitating syndrome directly accounting for 20% of cancer deaths without effective therapeutic approaches. It is extremely urgent to explore effective anti-cachexia drugs to ameliorate muscle and fat loss in cachexia patients.

Methods

Lewis lung carcinoma bearing C57BL/6 mice were applied as the animal model to examine the therapeutic effect of Coix seed oil (CSO) on cancer cachexia. The food intake and body weight change were monitored every 3 days throughout the experiment. The IL-6 and TNF-α levels in serum were detected by ELISA assay. Several key proteins involved in muscle wasting and fat lipolysis were tested by Western blot to identify the potential mechanism of CSO.

Results

Administration of CSO through gavage significantly prevented body weight loss and ameliorated systemic inflammation without affecting food intake and tumor size. The weight and histological morphology of gastrocnemius muscle and epididymal adipose tissue in CSO-treated mice were also improved. In mechanism, we found that CSO decreased the expression of MuRF1 and the ratio of phospho-p65 (Ser536) to p65 in muscle tissue. Meanwhile, cancer-induced activation of HSL and AMPK was also inhibited by CSO administration.

Conclusion

Coix seed oil exerts an anti-cachexia pharmaceutical effect by counteracting muscle and adipose tissue loss most likely through regulating NF-κB-MuRF1 and AMPK-HSL pathway.
Literature
1.
go back to reference Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.CrossRef Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.CrossRef
2.
go back to reference Loumaye A, Thissen JP. Biomarkers of cancer cachexia. Clin Biochem. 2017;50(18):1281–8.CrossRef Loumaye A, Thissen JP. Biomarkers of cancer cachexia. Clin Biochem. 2017;50(18):1281–8.CrossRef
3.
go back to reference Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–66.CrossRef Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153–66.CrossRef
4.
go back to reference Amano K, Maeda I, Morita T, Baba M, Miura T, Hama T, Mori I, Nakajima N, Nishi T, Sakurai H, et al. C-reactive protein, symptoms and activity of daily living in patients with advanced cancer receiving palliative care. J Cachexia Sarcopenia Muscle. 2017;8(3):457–65.CrossRef Amano K, Maeda I, Morita T, Baba M, Miura T, Hama T, Mori I, Nakajima N, Nishi T, Sakurai H, et al. C-reactive protein, symptoms and activity of daily living in patients with advanced cancer receiving palliative care. J Cachexia Sarcopenia Muscle. 2017;8(3):457–65.CrossRef
5.
go back to reference Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62.CrossRef Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–62.CrossRef
6.
go back to reference Op den Kamp CM, Langen RC, Snepvangers FJ, de Theije CC, Schellekens JM, Laugs F, Dingemans AM, Schols AM. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013;98(3):738–48.CrossRef Op den Kamp CM, Langen RC, Snepvangers FJ, de Theije CC, Schellekens JM, Laugs F, Dingemans AM, Schols AM. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr. 2013;98(3):738–48.CrossRef
7.
go back to reference Tisdale MJ. Is there a common mechanism linking muscle wasting in various disease types? Curr Opin Support Palliat Care. 2007;1(4):287–92.CrossRef Tisdale MJ. Is there a common mechanism linking muscle wasting in various disease types? Curr Opin Support Palliat Care. 2007;1(4):287–92.CrossRef
8.
go back to reference Li B, Wan L, Li Y, Yu Q, Chen P, Gan R, Yang Q, Han Y, Guo C. Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia. Tumour Biol. 2014;35(12):12415–25.CrossRef Li B, Wan L, Li Y, Yu Q, Chen P, Gan R, Yang Q, Han Y, Guo C. Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia. Tumour Biol. 2014;35(12):12415–25.CrossRef
9.
go back to reference Chen C, Ju R, Zhu L, Li J, Chen W, Zhang DC, Ye CY, Guo L. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-kappaB and activating SIRT1. Naunyn Schmiedeberg's Arch Pharmacol. 2017;390(4):423–33.CrossRef Chen C, Ju R, Zhu L, Li J, Chen W, Zhang DC, Ye CY, Guo L. Carboxyamidotriazole alleviates muscle atrophy in tumor-bearing mice by inhibiting NF-kappaB and activating SIRT1. Naunyn Schmiedeberg's Arch Pharmacol. 2017;390(4):423–33.CrossRef
10.
go back to reference Vaitkus JA, Celi FS. The role of adipose tissue in cancer-associated cachexia. Exp Biol Med (Maywood). 2017;242(5):473–81.CrossRef Vaitkus JA, Celi FS. The role of adipose tissue in cancer-associated cachexia. Exp Biol Med (Maywood). 2017;242(5):473–81.CrossRef
11.
go back to reference Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011;333(6039):233–8.CrossRef Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, Gorkiewicz G, Tamilarasan KP, Kumari P, Trauner M, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011;333(6039):233–8.CrossRef
12.
go back to reference Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103(10):2189–98.CrossRef Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones. Cancer. 2005;103(10):2189–98.CrossRef
13.
go back to reference Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, Kemp BE, Febbraio MA. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2006;290(3):E500–8.CrossRef Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, Kemp BE, Febbraio MA. Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2006;290(3):E500–8.CrossRef
14.
go back to reference Lee JH, Moon MH, Jeong JK, Park YG, Lee YJ, Seol JW, Park SY. Sulforaphane induced adipolysis via hormone sensitive lipase activation, regulated by AMPK signaling pathway. Biochem Biophys Res Commun. 2012;426(4):492–7.CrossRef Lee JH, Moon MH, Jeong JK, Park YG, Lee YJ, Seol JW, Park SY. Sulforaphane induced adipolysis via hormone sensitive lipase activation, regulated by AMPK signaling pathway. Biochem Biophys Res Commun. 2012;426(4):492–7.CrossRef
15.
go back to reference Rohm M, Schafer M, Laurent V, Ustunel BE, Niopek K, Algire C, Hautzinger O, Sijmonsma TP, Zota A, Medrikova D, et al. An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. Nat Med. 2016;22(10):1120–30.CrossRef Rohm M, Schafer M, Laurent V, Ustunel BE, Niopek K, Algire C, Hautzinger O, Sijmonsma TP, Zota A, Medrikova D, et al. An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice. Nat Med. 2016;22(10):1120–30.CrossRef
16.
go back to reference Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108–16.CrossRef Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108–16.CrossRef
17.
go back to reference Bai Y, Hu Y, Zhao Y, Yu X, Xu J, Hua Z, Zhao Z. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer. 2017;25(5):1651–9.CrossRef Bai Y, Hu Y, Zhao Y, Yu X, Xu J, Hua Z, Zhao Z. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer. 2017;25(5):1651–9.CrossRef
18.
go back to reference Schwartzberg LS, Arena FP, Bienvenu BJ, Kaplan EH, Camacho LH, Campos LT, Waymack JP, Tagliaferri MA, Chen MM, Li D. A randomized, open-label, safety and exploratory efficacy study of Kanglaite injection (KLTi) plus gemcitabine versus gemcitabine in patients with advanced pancreatic Cancer. J Cancer. 2017;8(10):1872–83.CrossRef Schwartzberg LS, Arena FP, Bienvenu BJ, Kaplan EH, Camacho LH, Campos LT, Waymack JP, Tagliaferri MA, Chen MM, Li D. A randomized, open-label, safety and exploratory efficacy study of Kanglaite injection (KLTi) plus gemcitabine versus gemcitabine in patients with advanced pancreatic Cancer. J Cancer. 2017;8(10):1872–83.CrossRef
19.
go back to reference Wu Y, Zhang J, Hong Y, Wang X. Effects of Kanglaite injection on serum miRNA-21 in patients with advanced lung Cancer. Med Sci Monit. 2018;24:2901–6.CrossRef Wu Y, Zhang J, Hong Y, Wang X. Effects of Kanglaite injection on serum miRNA-21 in patients with advanced lung Cancer. Med Sci Monit. 2018;24:2901–6.CrossRef
20.
go back to reference Woo JH, Li D, Wilsbach K, Orita H, Coulter J, Tully E, Kwon TK, Xu S, Gabrielson E. Coix seed extract, a commonly used treatment for cancer in China, inhibits NFkappaB and protein kinase C signaling. Cancer Biol Ther. 2007;6(12):2005–11.CrossRef Woo JH, Li D, Wilsbach K, Orita H, Coulter J, Tully E, Kwon TK, Xu S, Gabrielson E. Coix seed extract, a commonly used treatment for cancer in China, inhibits NFkappaB and protein kinase C signaling. Cancer Biol Ther. 2007;6(12):2005–11.CrossRef
21.
go back to reference Yu F, Gao J, Zeng Y, Liu CX. Inhibition of Coix seed extract on fatty acid synthase, a novel target for anticancer activity. J Ethnopharmacol. 2008;119(2):252–8.CrossRef Yu F, Gao J, Zeng Y, Liu CX. Inhibition of Coix seed extract on fatty acid synthase, a novel target for anticancer activity. J Ethnopharmacol. 2008;119(2):252–8.CrossRef
22.
go back to reference Liu Y, Zhang W, Wang XJ, Liu S. Antitumor effect of Kanglaite (R) injection in human pancreatic cancer xenografts. BMC Complement Altern Med. 2014;14:228.CrossRef Liu Y, Zhang W, Wang XJ, Liu S. Antitumor effect of Kanglaite (R) injection in human pancreatic cancer xenografts. BMC Complement Altern Med. 2014;14:228.CrossRef
23.
go back to reference Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31.CrossRef Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27–31.CrossRef
24.
go back to reference Sun R, Zhang S, Lu X, Hu W, Lou N, Zhao Y, Zhou J, Zhang X, Yang H. Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models. Oncol Rep. 2016;36(6):3291–302.CrossRef Sun R, Zhang S, Lu X, Hu W, Lou N, Zhao Y, Zhou J, Zhang X, Yang H. Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models. Oncol Rep. 2016;36(6):3291–302.CrossRef
25.
go back to reference Zhang G, Liu Z, Ding H, Zhou Y, Doan HA, Sin KWT, Zhu ZJ, Flores R, Wen Y, Gong X, et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat Commun. 2017;8(1):589.CrossRef Zhang G, Liu Z, Ding H, Zhou Y, Doan HA, Sin KWT, Zhu ZJ, Flores R, Wen Y, Gong X, et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat Commun. 2017;8(1):589.CrossRef
26.
go back to reference Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.CrossRef Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.CrossRef
27.
go back to reference Pan P, Wu Y, Guo ZY, Wang R, Wang YJ, Yuan YF. Antitumor activity and immunomodulatory effects of the intraperitoneal administration of Kanglaite in vivo in Lewis lung carcinoma. J Ethnopharmacol. 2012;143(2):680–5.CrossRef Pan P, Wu Y, Guo ZY, Wang R, Wang YJ, Yuan YF. Antitumor activity and immunomodulatory effects of the intraperitoneal administration of Kanglaite in vivo in Lewis lung carcinoma. J Ethnopharmacol. 2012;143(2):680–5.CrossRef
28.
go back to reference Huang X, Qin J, Lu S. Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantationinduced tumor growth. Mol Med Rep. 2014;10(4):2153–9.CrossRef Huang X, Qin J, Lu S. Kanglaite stimulates anticancer immune responses and inhibits HepG2 cell transplantationinduced tumor growth. Mol Med Rep. 2014;10(4):2153–9.CrossRef
29.
go back to reference Wang Y, Zhang C, Zhang S, Zhao Z, Wang J, Song J, Wang Y, Liu J, Hou S. Kanglaite sensitizes colorectal cancer cells to Taxol via NF-kappaBeta inhibition and connexin 43 upregulation. Sci Rep. 2017;7(1):1280.CrossRef Wang Y, Zhang C, Zhang S, Zhao Z, Wang J, Song J, Wang Y, Liu J, Hou S. Kanglaite sensitizes colorectal cancer cells to Taxol via NF-kappaBeta inhibition and connexin 43 upregulation. Sci Rep. 2017;7(1):1280.CrossRef
30.
go back to reference Liu X, Yang Q, Xi Y, Yu K, Wang W, Zhao X, Kou X. Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma. J Cancer Res Ther. 2014;10(Suppl 1):46–51.PubMed Liu X, Yang Q, Xi Y, Yu K, Wang W, Zhao X, Kou X. Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma. J Cancer Res Ther. 2014;10(Suppl 1):46–51.PubMed
31.
go back to reference Jiang Y, Yuan Q, Huang A, Fang Q. The synergistic mechanism of Pemetrexed followed by Kanglaite was due to KLT subsequently inhibiting the Pemetrexed-activated MAPK signaling pathway. Clin Lab. 2015;61(10):1353–63.PubMed Jiang Y, Yuan Q, Huang A, Fang Q. The synergistic mechanism of Pemetrexed followed by Kanglaite was due to KLT subsequently inhibiting the Pemetrexed-activated MAPK signaling pathway. Clin Lab. 2015;61(10):1353–63.PubMed
32.
go back to reference Qu D, Wang L, Liu M, Shen S, Li T, Liu Y, Huang M, Liu C, Chen Y, Mo R. Oral Nanomedicine based on multicomponent microemulsions for drug-resistant breast Cancer treatment. Biomacromolecules. 2017;18(4):1268–80.CrossRef Qu D, Wang L, Liu M, Shen S, Li T, Liu Y, Huang M, Liu C, Chen Y, Mo R. Oral Nanomedicine based on multicomponent microemulsions for drug-resistant breast Cancer treatment. Biomacromolecules. 2017;18(4):1268–80.CrossRef
33.
go back to reference Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017;170(3):548–63.e16.CrossRef Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017;170(3):548–63.e16.CrossRef
34.
go back to reference Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG, McMillan DC. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7(8):e41883.CrossRef Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG, McMillan DC. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7(8):e41883.CrossRef
35.
go back to reference Kim EY, Kim YS, Seo JY, Park I, Ahn HK, Jeong YM, Kim JH, Kim N. The relationship between sarcopenia and systemic inflammatory response for Cancer Cachexia in small cell lung Cancer. PLoS One. 2016;11(8):e0161125.CrossRef Kim EY, Kim YS, Seo JY, Park I, Ahn HK, Jeong YM, Kim JH, Kim N. The relationship between sarcopenia and systemic inflammatory response for Cancer Cachexia in small cell lung Cancer. PLoS One. 2016;11(8):e0161125.CrossRef
36.
go back to reference Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010;38(4):168–76.CrossRef Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010;38(4):168–76.CrossRef
37.
go back to reference Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8(4):321–7.CrossRef Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8(4):321–7.CrossRef
38.
go back to reference Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009;3(4):263–8.CrossRef Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009;3(4):263–8.CrossRef
39.
go back to reference Zhou W, Jiang ZW, Tian J, Jiang J, Li N, Li JS. Role of NF-kappaB and cytokine in experimental cancer cachexia. World J Gastroenterol. 2003;9(7):1567–70.CrossRef Zhou W, Jiang ZW, Tian J, Jiang J, Li N, Li JS. Role of NF-kappaB and cytokine in experimental cancer cachexia. World J Gastroenterol. 2003;9(7):1567–70.CrossRef
40.
go back to reference Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–98.CrossRef Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119(2):285–98.CrossRef
41.
go back to reference Maguire O, O'Loughlin K, Minderman H. Simultaneous assessment of NF-kappaB/p65 phosphorylation and nuclear localization using imaging flow cytometry. J Immunol Methods. 2015;423:3–11.CrossRef Maguire O, O'Loughlin K, Minderman H. Simultaneous assessment of NF-kappaB/p65 phosphorylation and nuclear localization using imaging flow cytometry. J Immunol Methods. 2015;423:3–11.CrossRef
42.
go back to reference Pijet B, Pijet M, Litwiniuk A, Gajewska M, Pajak B, Orzechowski A. TNF- alpha and IFN-s-dependent muscle decay is linked to NF-kappaB- and STAT-1alpha-stimulated Atrogin1 and MuRF1 genes in C2C12 myotubes. Mediat Inflamm. 2013;2013:171437.CrossRef Pijet B, Pijet M, Litwiniuk A, Gajewska M, Pajak B, Orzechowski A. TNF- alpha and IFN-s-dependent muscle decay is linked to NF-kappaB- and STAT-1alpha-stimulated Atrogin1 and MuRF1 genes in C2C12 myotubes. Mediat Inflamm. 2013;2013:171437.CrossRef
43.
go back to reference Shi G, Zheng X, Zhang S, Wu X, Yu F, Wang Y, Xing F. Kanglaite inhibits EMT caused by TNF-alpha via NF-kappaBeta inhibition in colorectal cancer cells. Oncotarget. 2018;9(6):6771–9.CrossRef Shi G, Zheng X, Zhang S, Wu X, Yu F, Wang Y, Xing F. Kanglaite inhibits EMT caused by TNF-alpha via NF-kappaBeta inhibition in colorectal cancer cells. Oncotarget. 2018;9(6):6771–9.CrossRef
44.
go back to reference Kim SJ, Tang T, Abbott M, Viscarra JA, Wang Y, Sul HS. AMPK phosphorylates Desnutrin/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue. Mol Cell Biol. 2016;36(14):1961–76.CrossRef Kim SJ, Tang T, Abbott M, Viscarra JA, Wang Y, Sul HS. AMPK phosphorylates Desnutrin/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue. Mol Cell Biol. 2016;36(14):1961–76.CrossRef
45.
go back to reference Ahmadian M, Abbott MJ, Tang T, Hudak CS, Kim Y, Bruss M, Hellerstein MK, Lee HY, Samuel VT, Shulman GI, et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab. 2011;13(6):739–48.CrossRef Ahmadian M, Abbott MJ, Tang T, Hudak CS, Kim Y, Bruss M, Hellerstein MK, Lee HY, Samuel VT, Shulman GI, et al. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab. 2011;13(6):739–48.CrossRef
46.
go back to reference Fruhbeck G, Mendez-Gimenez L, Fernandez-Formoso JA, Fernandez S, Rodriguez A. Regulation of adipocyte lipolysis. Nutr Res Rev. 2014;27(1):63–93.CrossRef Fruhbeck G, Mendez-Gimenez L, Fernandez-Formoso JA, Fernandez S, Rodriguez A. Regulation of adipocyte lipolysis. Nutr Res Rev. 2014;27(1):63–93.CrossRef
47.
go back to reference Miao C, Lv Y, Zhang W, Chai X, Feng L, Fang Y, Liu X, Zhang X. Pyrrolidine Dithiocarbamate (PDTC) attenuates Cancer Cachexia by affecting muscle atrophy and fat lipolysis. Front Pharmacol. 2017;8:915.CrossRef Miao C, Lv Y, Zhang W, Chai X, Feng L, Fang Y, Liu X, Zhang X. Pyrrolidine Dithiocarbamate (PDTC) attenuates Cancer Cachexia by affecting muscle atrophy and fat lipolysis. Front Pharmacol. 2017;8:915.CrossRef
Metadata
Title
Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis
Authors
Huiquan Liu
Lu Li
Jun Zou
Ting Zhou
Bangyan Wang
Huihui Sun
Shiying Yu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2019
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-019-2684-4

Other articles of this Issue 1/2019

BMC Complementary Medicine and Therapies 1/2019 Go to the issue